Hospital
BRFHH Shreveport LLC
BRFHH Shreveport LLC was paid $6.30M by Medicaid between Jan 2018 and Oct 2018, across 289 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 16% of everything it billed.
33Billing provider infoBRFHH SHREVEPORT LLC
SHREVEPORT, LA 71103
SHREVEPORT, LA 71103
33aNPI1912909912assigned 08/10/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.30M
24GClaims337,881
24DCodes billed289
24AFirst – last monthJan 2018 – Oct 2018
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#43 of 96
Median peer was paid$5.17M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 337,881 | $6.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 16% | 38,193 | 34,616 | $977K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 23,442 | 19,749 | $669K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.1% | 4,749 | 4,405 | $383K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.0% | 3,064 | 2,793 | $378K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.6% | 5,470 | 5,130 | $290K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.4% | 5,267 | 4,437 | $215K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 2.9% | 6,446 | 5,442 | $181K |
| 80053 | Comprehensive metabolic panel | 2.7% | 21,328 | 16,495 | $173K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 3,782 | 3,532 | $135K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.1% | 3,784 | 3,534 | $135K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2.0% | 1,116 | 1,003 | $125K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.0% | 551 | 520 | $125K |
277 more codes
| 99285 | Emergency room visit (most serious) | 1.9% | 558 | $121K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 19,051 | $104K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.4% | 3,555 | $91K |
| 31575 | 1.4% | 422 | $89K | |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 50,349 | $87K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.3% | 914 | $84K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 1,787 | $73K |
| 95811 | <1% | 202 | $60K | |
| J9310 | Injection, rituximab, 100 mg | <1% | 16 | $52K |
| 59025 | Fetal non-stress test | <1% | 898 | $51K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 437 | $50K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,217 | $48K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,296 | $47K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 297 | $47K |
| 31231 | <1% | 160 | $44K | |
| 90378 | <1% | 45 | $39K | |
| G0378 | Hospital observation service, per hour | <1% | 529 | $39K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,502 | $36K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,378 | $35K |
| 77386 | <1% | 139 | $35K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,336 | $34K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 915 | $32K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,274 | $31K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 501 | $31K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,469 | $29K |
| 81025 | <1% | 5,462 | $29K | |
| 54150 | <1% | 87 | $29K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,005 | $27K |
| 81003 | <1% | 13,152 | $27K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 102 | $27K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 89 | $27K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 96 | $25K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 65 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,718 | $24K |
| 80050 | General health panel | <1% | 673 | $23K |
| 87536 | <1% | 542 | $23K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 52 | $22K |
| 92134 | <1% | 1,297 | $22K | |
| 16020 | <1% | 101 | $21K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 606 | $19K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,677 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 584 | $16K |
| 86780 | <1% | 1,280 | $16K | |
| 80074 | <1% | 421 | $15K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 813 | $15K |
| 85027 | <1% | 2,832 | $15K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 38 | $14K |
| 80061 | Lipid panel | <1% | 1,423 | $14K |
| 82962 | <1% | 7,184 | $14K | |
| 76801 | <1% | 314 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,658 | $12K |
| 36430 | <1% | 256 | $11K | |
| 93325 | <1% | 161 | $10K | |
| 84439 | <1% | 1,230 | $10K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 18 | $10K |
| 67228 | <1% | 52 | $10K | |
| 86762 | <1% | 782 | $10K | |
| 80320 | <1% | 825 | $10K | |
| 76775 | <1% | 274 | $10K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 237 | $10K |
| 97602 | <1% | 122 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 258 | $10K |
| 82728 | <1% | 1,164 | $10K | |
| 82607 | <1% | 749 | $10K | |
| 83970 | <1% | 400 | $10K | |
| 88184 | <1% | 484 | $9K | |
| 81001 | <1% | 4,123 | $9K | |
| 87522 | Neg quan hep c or qual rna | <1% | 289 | $9K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 222 | $9K |
| 82746 | <1% | 716 | $9K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 16 | $9K |
| 87340 | <1% | 928 | $9K | |
| 93299 | <1% | 24 | $8K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 251 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 246 | $8K |
| 86160 | <1% | 957 | $8K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 196 | $8K |
| 51798 | <1% | 511 | $7K | |
| 86850 | <1% | 2,050 | $7K | |
| 85046 | <1% | 1,638 | $7K | |
| 76820 | <1% | 389 | $7K | |
| 76813 | <1% | 77 | $7K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 696 | $7K |
| 97597 | <1% | 187 | $7K | |
| 94660 | <1% | 126 | $7K | |
| 40800 | <1% | 37 | $6K | |
| 93320 | <1% | 96 | $6K | |
| 86140 | <1% | 1,547 | $6K | |
| 97165 | <1% | 135 | $6K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 27 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 260 | $6K |
| 97161 | <1% | 141 | $6K | |
| 87902 | <1% | 36 | $6K | |
| 77336 | <1% | 168 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,090 | $6K |
| 92083 | <1% | 542 | $5K | |
| 92133 | <1% | 774 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 70 | $5K |
| 86225 | <1% | 531 | $5K | |
| 11719 | <1% | 325 | $5K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 18 | $5K |
| 86920 | <1% | 329 | $5K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 233 | $5K |
| 97750 | <1% | 426 | $5K | |
| 73610 | <1% | 280 | $5K | |
| 86901 | <1% | 2,068 | $5K | |
| 82570 | <1% | 1,265 | $4K | |
| 85610 | <1% | 1,869 | $4K | |
| 83735 | <1% | 905 | $4K | |
| 94375 | <1% | 64 | $4K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 84 | $4K |
| 86900 | <1% | 2,068 | $4K | |
| 87210 | <1% | 1,256 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 20 | $4K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 413 | $4K |
| 80069 | <1% | 762 | $4K | |
| 73130 | <1% | 209 | $4K | |
| 95115 | <1% | 195 | $4K | |
| 99195 | <1% | 222 | $3K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 16 | $3K |
| 86592 | <1% | 883 | $3K | |
| 97760 | <1% | 216 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 901 | $3K |
| 29705 | <1% | 142 | $3K | |
| 85660 | <1% | 816 | $3K | |
| 73110 | <1% | 202 | $3K | |
| 52000 | <1% | 13 | $3K | |
| 92557 | <1% | 59 | $3K | |
| 84156 | <1% | 1,099 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $3K |
| 57454 | <1% | 14 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 79 | $3K |
| 73562 | <1% | 147 | $3K | |
| 58100 | <1% | 29 | $2K | |
| 84481 | <1% | 277 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 82 | $2K |
| 83615 | <1% | 674 | $2K | |
| 71250 | <1% | 57 | $2K | |
| 74178 | <1% | 14 | $2K | |
| 93304 | <1% | 18 | $2K | |
| 83655 | <1% | 157 | $2K | |
| 84153 | <1% | 111 | $2K | |
| 97168 | <1% | 79 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 673 | $2K |
| 85018 | <1% | 689 | $2K | |
| 93321 | <1% | 31 | $2K | |
| 96415 | <1% | 48 | $2K | |
| 85730 | <1% | 392 | $2K | |
| 88142 | <1% | 143 | $2K | |
| 83516 | <1% | 172 | $2K | |
| 97162 | <1% | 34 | $2K | |
| 99156 | <1% | 984 | $2K | |
| 87081 | <1% | 232 | $1K | |
| 29075 | <1% | 16 | $1K | |
| 84702 | <1% | 95 | $1K | |
| 92020 | <1% | 452 | $1K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 75 | $1K |
| 83021 | <1% | 106 | $1K | |
| 83550 | <1% | 231 | $1K | |
| 77300 | <1% | 14 | $1K | |
| 84484 | <1% | 177 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 35 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 146 | $1K |
| 82977 | <1% | 165 | $1K | |
| 82248 | <1% | 287 | $1K | |
| 90686 | <1% | 1,152 | $1K | |
| 70355 | <1% | 231 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 741 | $996.59 |
| 92567 | <1% | 69 | $948.23 | |
| 90715 | <1% | 258 | $942.90 | |
| 11056 | <1% | 37 | $942.63 | |
| 84163 | <1% | 53 | $890.86 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 28 | $869.82 |
| 73630 | <1% | 62 | $869.66 | |
| 83690 | <1% | 141 | $847.66 | |
| 86336 | <1% | 54 | $829.04 | |
| 86704 | <1% | 81 | $815.36 | |
| 83540 | <1% | 243 | $803.97 | |
| 84100 | <1% | 250 | $796.32 | |
| 77280 | <1% | 16 | $781.80 | |
| 87070 | <1% | 93 | $688.10 | |
| 82043 | <1% | 182 | $676.69 | |
| 85651 | <1% | 214 | $655.62 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 68 | $651.54 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $641.03 |
| 73560 | <1% | 34 | $624.07 | |
| 82950 | <1% | 187 | $609.30 | |
| 96402 | <1% | 55 | $585.64 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 15 | $576.06 |
| 11055 | <1% | 17 | $550.16 | |
| 73590 | <1% | 31 | $549.42 | |
| 70486 | <1% | 61 | $520.65 | |
| 87186 | <1% | 102 | $515.37 | |
| 86905 | <1% | 208 | $505.04 | |
| 80299 | <1% | 44 | $504.92 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,566 | $504.27 |
| 99157 | <1% | 292 | $482.88 | |
| 96111 | <1% | 112 | $470.69 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,463 | $460.27 |
| 82150 | <1% | 75 | $414.34 | |
| 87077 | <1% | 86 | $411.31 | |
| 86706 | <1% | 35 | $376.13 | |
| 97010 | <1% | 403 | $350.87 | |
| 87205 | <1% | 93 | $346.82 | |
| 77065 | Tomosynthesis, mammo | <1% | 15 | $345.59 |
| 74018 | <1% | 16 | $344.49 | |
| 86430 | <1% | 71 | $337.50 | |
| 76519 | <1% | 37 | $331.74 | |
| 86803 | <1% | 36 | $327.37 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 600 | $326.11 |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 19 | $318.60 |
| 93990 | <1% | 15 | $298.42 | |
| 86593 | <1% | 76 | $281.58 | |
| 86705 | <1% | 39 | $269.99 | |
| 86709 | <1% | 39 | $258.40 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 39 | $246.63 |
| 84550 | <1% | 71 | $232.30 | |
| 76000 | <1% | 32 | $231.96 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 67 | $198.12 |
| 84244 | <1% | 13 | $196.72 | |
| 82542 | <1% | 13 | $196.38 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 17 | $162.87 |
| 82397 | <1% | 44 | $157.76 | |
| 84165 | <1% | 39 | $144.46 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 12 | $121.50 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 36 | $115.82 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 27 | $110.65 |
| 83883 | <1% | 76 | $103.81 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 194 | $103.49 |
| 90670 | <1% | 1,027 | $100.54 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 16 | $96.10 |
| C1769 | Guide wire | <1% | 51 | $93.43 |
| 92504 | <1% | 29 | $76.53 | |
| 76942 | <1% | 54 | $65.94 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 17 | $57.72 |
| 87147 | <1% | 12 | $54.24 | |
| C1819 | Surgical tissue localization and excision device (implantable) | <1% | 102 | $51.27 |
| 99188 | <1% | 265 | $43.42 | |
| 90723 | <1% | 587 | $33.77 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 14 | $33.72 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 88 | $31.03 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 113 | $26.98 |
| 90680 | <1% | 403 | $22.77 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 555 | $18.48 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 83 | $16.60 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,812 | $15.63 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 50 | $4.15 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 302 | $0.00 |
| 90648 | 0% | 986 | $0.00 | |
| 90633 | 0% | 770 | $0.00 | |
| 90685 | 0% | 193 | $0.00 | |
| C1752 | Catheter, hemodialysis/peritoneal, short-term | 0% | 1,057 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 78 | $0.00 |
| 90700 | 0% | 107 | $0.00 | |
| 90710 | 0% | 172 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 81 | $0.00 |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | 0% | 50 | $0.00 |
| 90707 | 0% | 65 | $0.00 | |
| C9257 | Injection, bevacizumab, 0.25 mg | 0% | 15 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 41 | $0.00 |
| 90734 | 0% | 17 | $0.00 | |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 41 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 15 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 166 | $0.00 |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | 0% | 31 | $0.00 |
| J0178 | Injection, aflibercept, 1 mg | 0% | 168 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 87 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 91 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 28 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 12 | $0.00 |
| 90696 | 0% | 186 | $0.00 | |
| C1783 | Ocular implant, aqueous drainage assist device | 0% | 13 | $0.00 |
| A9270 | Non-covered item or service | 0% | 24 | $0.00 |
| 81511 | 0% | 67 | $0.00 | |
| 90716 | 0% | 53 | $0.00 | |
| 88342 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOORE, VERNON (CFO)
| Provider | Location | Paid |
|---|---|---|
| Yuma Regional Medical Center | Yuma, AZ | $278.42M |
| University Health Shreveport LLC | Shreveport, LA | $2.60M |
| Yuma Regional Medical Center | Yuma, AZ | $1.18M |
| BRFHH Shreveport LLC | Shreveport, LA | $494K |
| University Health Shreveport LLC | Shreveport, LA | $350K |
| BRFHH Shreveport LLC | Shreveport, LA | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.